OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Cognitive Aging and Cognitive Impairment
Submission Deadline: July 15, 2022 (Open) Submit Now
Sara Bottiroli, PhD
Associate Professor, Headache Science Centre and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia Via Mondino, 2 - Pavia - Italy
Research Interests: Cognitive function; Metacognition
About This Topic
Most Western societies have an increasing number of older adults. Consequently, the relevance of cognitive decline and dementia on the healthcare system has determined that the topic of cognitive changes that occur in normal and pathological aging stimulates action from many perspectives. This is because it is mandatory to define and identify the cognitive changes that occur across the lifespan in normal and pathological aging. Cognitive aging relates to all these abilities involved in daily life, such as executive functioning, memory, decision making, to name a few, and the mechanisms responsible. Cognitive impairment refers to those deficits that characterize the transitional stages between normal and pathological aging, such as Mild Cognitive Impairment and Subjective Cognitive Decline, as well as dementia itself. The interest here is in understanding the risk and protective factors of deterioration along with the need for early diagnosis and intervention. Indeed, early differentiation between normal and pathological aging is mandatory in order to promptly define appropriate treatment that helps postpone further cognitive decline.
Therefore, the goal of this Research Topic is to bring together the latest findings on cognitive aging and cognitive impairment. We are particularly interested in mapping key developments, innovations, and future directions in this field. This Research Topic welcomes original research, reviews, case reports, short article types, and others that address, monitor, and evaluate normal and pathological aging. We encourage submissions from across the discipline of psychology (neuropsychology, cognitive and applied psychology, and cognitive neuroscience).
Received: 27 December 2021; Published: 08 September 2022; doi: 10.21926/obm.geriatr.2203203
Individuals with Alzheimer’s disease (AD) and Mild Cognitive Impairment (MCI) have increased gait disturbances throughout disease progression. However, an understanding of gait impairment and progression in early versus late AD is lacking. Further, the longitudinal progression of gait impairment in AD as well as in those with [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.